BioSyent Inc.
TSXV: RX.V0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Toronto Stock Exchange Ventures
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- René C. Goehrum
- Employees
- 60
- Headquarters
- Mississauga, Canada
- IPO year
- 1996
- Market cap
- CA$169.0M
- Website
- https://www.biosyent.com
Loading RX…
Loading profile data…Frequently asked questions about RX
What does BioSyent Inc. (RX.V) do?
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd T...
Where does RX.V trade?
BioSyent Inc. (RX.V) trades on the Toronto Stock Exchange Ventures.
What sector is RX.V in?
BioSyent Inc. (RX.V) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of BioSyent Inc.?
René C. Goehrum is the chief executive officer of BioSyent Inc. (RX.V).
Where is BioSyent Inc. headquartered?
BioSyent Inc. is headquartered in Canada.
Does RX.V pay a dividend?
Yes — BioSyent Inc. (RX.V) paid a trailing twelve-month dividend of CAD 0.20 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did RX.V go public?
BioSyent Inc. (RX.V) completed its initial public offering in 1996.